The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Understanding the Market Dynamics

• The influenza vaccines market has experienced robust growth in recent years.
• From $6.91 billion in 2023, it is projected to reach $7.44 billion in 2024, with a Compound Annual Growth Rate (CAGR) of 7.6%.
• Factors driving historic growth include pandemic preparedness, public health initiatives, vaccine effectiveness studies, healthcare professional recommendations, and global influenza surveillance.
• The market is expected to continue expanding, reaching $10.1 billion in 2028, with a CAGR of 8.0%.
• Forecasted growth drivers include climate and environmental factors, improved healthcare accessibility, emergence of new influenza strains, innovation in adjuvants and delivery systems, and rising healthcare expenditure.

Read More On The Influenza Vaccines Market Report 2024 – https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

The Rising Incidences of Seasonal Influenza Drive Market Growth

• Seasonal influenza, caused by influenza viruses circulating during specific times of the year, is on the rise.
• Factors contributing to this increase include antigenic drift, population susceptibility, environmental factors, incomplete vaccine coverage, and lack of universal vaccination.
• Influenza vaccines play a crucial role in reducing the incidences of seasonal influenza.
• The Central Drugs Standard Control Organization reported significant influenza burdens, underscoring the importance of vaccination.
• Major companies driving the market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and others.

Adoption of Technologically Advanced Vaccine Production

• Technological advancements in vaccine production are becoming increasingly prevalent in the influenza vaccines market.
• Companies are embracing advanced technologies to enhance their market position.
• Notable innovations include GlaxoSmithKline PLC’s Multiple Antigen Presenting System (MAPS) for vaccine development, enabling rapid response to epidemics or pandemics.
• Pfizer’s collaboration with BioNTech SE to develop an mRNA combination vaccine for influenza and COVID-19 showcases the industry’s commitment to innovation.

Segmentation of the Influenza Vaccines Market

• The market is segmented based on vaccine type, valency, route of administration, age group, and distribution channel.
• Vaccine types include inactivated and live attenuated vaccines, while valency encompasses quadrivalent and trivalent vaccines.
• Route of administration options include injection and nasal spray.
• Age group categories cover pediatric and adult populations.
• Distribution channels include hospitals and pharmacies, government and institutional supply, and other distribution channels.

Regional Insights

• North America led the influenza vaccines market in 2023.
• Asia-Pacific is expected to witness the fastest growth in the forecast period.

Conclusion

• The influenza vaccines market is poised for substantial growth, driven by factors such as rising incidences of seasonal influenza and adoption of technologically advanced vaccine production.
• Collaborations and innovations within the industry demonstrate a commitment to addressing evolving healthcare challenges.
• Segmentation and regional insights provide a comprehensive understanding of market dynamics.
• As the market continues to expand, stakeholders must remain agile and responsive to emerging trends and opportunities.

Request for A Sample Of The Global Influenza Vaccines Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=11935&type=smp